Long-term follow-up of Graves ophthalmopathy in an incidence cohort

被引:99
作者
Bartley, GB
Fatourechi, V
Kadrmas, EF
Jacobsen, SJ
Ilstrup, DM
Garrity, JA
Gorman, CA
机构
[1] MAYO CLIN & MAYO FDN,DIV ENDOCRINOL METAB & INTERNAL MED,ROCHESTER,MN 55905
[2] MAYO CLIN & MAYO FDN,DEPT HLTH SCI RES,ROCHESTER,MN 55905
关键词
D O I
10.1016/S0161-6420(96)30579-4
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose: To provide long-term follow-up data on patients with Graves ophthalmopathy in an incidence cohort of 120 patients. Methods: Data were obtained from a comprehensive review of each patient's community medical record, a follow-up survey, or both. Results: The median interval between the initial ophthalmic examination and most recent follow-up was 9.8 years (range, 64 days to 17.4 years). Follow-up of more than 5 years was available for 96 patients (80.0%), whereas follow-up exceeding 10 years was achieved for 59 patients (49.2%). Persistent visual loss from optic neuropathy occurred in two eyes, with final visual acuities of 20/30 and 20/60, respectively. None of the patients reported deterioration of vision attributable to Graves ophthalmopathy in the interval since their last ophthalmic examination at the authors' institution. Two patients (2.2%) had constant diplopia, but it was correctable with spectacles (prisms) in each case. Nearly one third of respondents had had ocular discomfort during the preceding 4 weeks; the most frequent cause in 72% of patients was dry eyes. Among the respondents to the survey, 60.5% believed that the appearance of their eyes had not returned to what it had been before the development of thyroid disease, 51.6% thought that their eyes appeared abnormal, and 37.9% were dissatisfied with the appearance of their eyes. Conclusions. Although with treatment few patients have long-term functional impairment from Graves ophthalmopathy, more than one third of patients are dissatisfied with their ultimate appearance. The psychologic, aesthetic, economic, and social sequelae of the disorder require further definition by formal outcomes studies.
引用
收藏
页码:958 / 962
页数:5
相关论文
共 26 条
[1]  
ARANOW H, 1965, J CLIN ENDOCR METAB, V25, P1
[2]   CHOICE OF THERAPY AND CRITERIA FOR ASSESSING TREATMENT OUTCOME IN THYROID-ASSOCIATED OPHTHALMOPATHY [J].
BAHN, RS ;
GORMAN, CA .
ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, 1987, 16 (02) :391-407
[3]  
Bartley G B, 1994, Trans Am Ophthalmol Soc, V92, P477
[4]   Clinical features of Graves' ophthalmopathy in an incidence cohort [J].
Bartley, GB ;
Fatourechi, V ;
Kadrmas, EF ;
Jacobsen, SJ ;
Ilstrup, DM ;
Garrity, JA ;
Gorman, CA .
AMERICAN JOURNAL OF OPHTHALMOLOGY, 1996, 121 (03) :284-290
[5]   The treatment of Graves' ophthalmopathy in an incidence cohort [J].
Bartley, GB ;
Fatourechi, V ;
Kadrmas, EF ;
Jacobsen, SJ ;
Ilstrup, DM ;
Garrity, JA ;
Gorman, CA .
AMERICAN JOURNAL OF OPHTHALMOLOGY, 1996, 121 (02) :200-206
[6]   THE INCIDENCE OF GRAVES OPHTHALMOPATHY IN OLMSTED COUNTY, MINNESOTA [J].
BARTLEY, GB ;
FATOURECHI, V ;
KADRMAS, EF ;
JACOBSEN, SJ ;
ILSTRUP, DM ;
GARRITY, JA ;
GORMAN, CA .
AMERICAN JOURNAL OF OPHTHALMOLOGY, 1995, 120 (04) :511-517
[7]  
BARTLEY GB, IN PRESS AM J OPHTHA
[8]  
DAY RM, 1962, ARCH OPHTHALMOL-CHIC, V67, P289
[9]  
FATOURECHI V, 1994, OPHTHALMOLOGY, V101, P938
[10]  
FELDON SE, 1984, FOCAL POINTS CLIN MO